drugset / Trial / NCT01886820
A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem Histopathology
NaSingle-groupOpen-labelDiagnostic
Summary
To Determine the the Efficacy and Safety of \[18F\]NAV4694 PET for Detection of Cerebral β-Amyloid When Compared With Postmortem Histopathology
Timeline
- Start
- 2013-06
- Primary completion
- 2018-06
- Completion
- 2018-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | [18F]NAV4694 | Diagnostic / imaging agent | 300 mbq | Intravenous |